Overview

Sorafenib in Relapsed High Grade Osteosarcoma

Status:
Completed

Trial end date:
2011-06-01

Target enrollment:

Participant gender:

Summary

Aim of this exploratory phase II study is to assess the clinical activity of sorafenib as single agent, in terms of percentage of patients with high grade advanced osteosarcoma free from progression following 4 months of therapy

Phase:

Phase 2

Details

Lead Sponsor:

Italian Sarcoma Group

Treatments:

Niacinamide
Sorafenib